Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
$0.00
$0.00
$0.00
N/A1.561,100 shsN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
$0.00
+∞
$0.00
$0.00
$0.00
N/A1.98N/A2,200 shs
AKSY
Aksys
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
$0.00
$0.00
$0.00
N/AN/AN/AN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
0.00%0.00%-75.00%-75.00%-83.33%
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00%0.00%0.00%0.00%0.00%
AKSY
Aksys
0.00%0.00%0.00%0.00%0.00%
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/AN/AN/AN/AN/AN/AN/A
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
0.00
N/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00
N/AN/AN/A
AKSY
Aksys
0.00
N/AN/AN/A
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
$270KN/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/AN/AN/AN/AN/A
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
-$510KN/A0.00N/AN/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/A0.00N/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
N/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/AN/AN/AN/A
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
N/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/A
AKSY
Aksys
N/A
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
N/A

Insider Ownership

CompanyInsider Ownership
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
34.11%
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
17.40%
AKSY
Aksys
3.80%
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
15.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
20N/AN/ANot Optionable
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
6830,000N/ANot Optionable
AKSY
Aksys
87N/AN/ANot Optionable
Pathfinder Cell Therapy Inc. stock logo
PFND
Pathfinder Cell Therapy
1N/AN/ANot Optionable

Recent News About These Companies

t-cell therapy
Pathfinder Cell Therapy, Inc. (PFND)
Cell Therapy Repairs Cornea Damage With Patient’s Own Stem Cells
Stem cell therapy for type 1 diabetes mellitus
Cell Replacement Therapy for Parkinson's Disease
Gene and Cell Therapy
Your First Therapy Session
Therapy for Teens: What to Expect
Therapy: Does It Ever End?
Advanced Biomedical Technologies stock logo

Advanced Biomedical Technologies OTCMKTS:ABMT

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.

Alliqua BioMedical stock logo

Alliqua BioMedical OTCMKTS:ADYX

$0.0001 +0.00 (+∞)
As of 07/15/2025 05:20 PM Eastern

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Aksys OTCMKTS:AKSY

Aksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure. The company offers an automated personal hemodialysis system, known as the Aksys PHD, a Personal Hemodialysis System (PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites, such as their own homes. The PHD System is designed to monitor, during the treatment, various vital statistics, including the patient's blood flow rate, the amount of water removed from the patient, the length of the treatment session, and other parameters. It also evaluates the performance of the artificial kidney in removing toxins from the patient's blood prior to each treatment, as well as automatically evaluates the water treatment filters and indicates whether a replacement is required and verifies that safety systems, sensors, and alarms are operating correctly. Aksys Ltd. also provides various services, including the delivery and installation of the PHD System; technical services, including maintenance and repair of the PHD System; delivery of consumables used in dialysis, such as the water purification components and dialysate concentrate; and artificial kidney, and arterial and venous blood tubing. The company markets its products and services, primarily to healthcare providers, such as hospitals, dialysis clinics, managed care organizations, and nephrology physician groups in the United States, the United Kingdom, and Japan. Aksys Ltd. was founded in 1991 and is headquartered in Lincolnshire, Illinois.

Pathfinder Cell Therapy stock logo

Pathfinder Cell Therapy OTCMKTS:PFND

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.